Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Rating of “Hold” by Analysts

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) has earned a consensus rating of “Hold” from the five brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $17.00.

A number of equities analysts have recently commented on VRCA shares. Wall Street Zen lowered shares of Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Zacks Research cut shares of Verrica Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 9th. TD Cowen reissued a “buy” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, January 7th. Loop Capital set a $17.00 price target on shares of Verrica Pharmaceuticals in a research report on Thursday, December 18th. Finally, raised shares of Verrica Pharmaceuticals from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a report on Thursday, December 18th.

Hedge Funds Weigh In On Verrica Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Armistice Capital LLC raised its holdings in shares of Verrica Pharmaceuticals by 3.7% in the 2nd quarter. Armistice Capital LLC now owns 8,881,344 shares of the company’s stock valued at $4,708,000 after acquiring an additional 313,944 shares in the last quarter. State Street Corp grew its holdings in shares of Verrica Pharmaceuticals by 14.1% during the fourth quarter. State Street Corp now owns 23,481 shares of the company’s stock worth $195,000 after purchasing an additional 2,900 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new position in shares of Verrica Pharmaceuticals during the fourth quarter worth about $188,000. Goldman Sachs Group Inc. bought a new position in shares of Verrica Pharmaceuticals in the fourth quarter worth approximately $155,000. Finally, HRT Financial LP bought a new position in shares of Verrica Pharmaceuticals in the fourth quarter worth approximately $144,000. 42.45% of the stock is currently owned by institutional investors.

Verrica Pharmaceuticals Stock Performance

Shares of VRCA opened at $5.45 on Monday. Verrica Pharmaceuticals has a 52-week low of $3.28 and a 52-week high of $9.82. The stock’s 50-day simple moving average is $6.43 and its 200 day simple moving average is $5.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.45 and a current ratio of 2.59. The stock has a market capitalization of $93.63 million, a price-to-earnings ratio of -3.45 and a beta of 1.47.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its earnings results on Wednesday, March 11th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). The business had revenue of $5.09 million during the quarter, compared to analyst estimates of $4.52 million. Research analysts forecast that Verrica Pharmaceuticals will post -1.46 EPS for the current fiscal year.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.